Reinaldo Gutierrez, MD
Internal Medicine · Hicksville, NYNPI 1356346373
Payments from drug & device makers
Across 175 payments — averaging $27.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$924
- AbbVie$700
- Merck$420
- Novo Nordisk$394
- Pfizer$276
- Medtronic$237
- plus $2K from 31 others
What the payments were for
- Food & beverage$4,805100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 26 | $924 |
| AbbVie | 27 | $700 |
| Merck | 23 | $420 |
| Novo Nordisk | 19 | $394 |
| Pfizer | 13 | $276 |
| Medtronic(2 entities) | 3 | $237 |
| Amgen | 7 | $200 |
| Intercept Pharmaceuticals, Inc. | 2 | $177 |
| E.r. Squibb & Sons, L.L.C. | 4 | $169 |
| Atricure, Inc. | 1 | $145 |
| Renalytix AI, Inc. | 2 | $141 |
| Boehringer Ingelheim | 5 | $129 |
| Echosens North America, Inc. | 2 | $104 |
| AstraZeneca | 6 | $89 |
| Currax Pharmaceuticals LLC | 5 | $83 |
| Boston Scientific | 3 | $75 |
| Amarin Pharma, Inc. | 4 | $71 |
| Inspire Medical Systems, Inc. | 2 | $61 |
| Abbott | 2 | $43 |
| GSK | 2 | $31 |
| Daiichi Sankyo Inc. | 1 | $24 |
| Astellas Pharma US Inc | 1 | $24 |
| Virtus Pharmaceuticals LLC | 1 | $24 |
| Eisai Inc. | 1 | $24 |
| Ultragenyx Pharmaceutical Inc. | 1 | $24 |
| Shield Therapeutics Inc | 1 | $22 |
| Sanofi | 1 | $21 |
| Exact Sciences | 1 | $20 |
| Bausch Health US, LLC | 1 | $20 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $20 |
| Johnson & Johnson | 1 | $18 |
| Orthofix Medical, Inc. | 1 | $18 |
| Corcept Therapeutics | 1 | $18 |
| Sanofi Pasteur Inc. | 1 | $17 |
| Seqirus USA Inc | 1 | $15 |
| Philips North America LLC | 1 | $14 |
| Aytu Biopharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,805 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 217 | $232,671 |
| MounjaroTirzepatide | 196 | $212,936 |
| EliquisApixaban | 73 | $97,404 |
| FarxigaDapagliflozin Propanediol | 52 | $69,881 |
| JardianceEmpagliflozin | 58 | $67,836 |
| JanuviaSitagliptin Phosphate | 54 | $59,570 |
| WegovySemaglutide | 15 | $20,820 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $18,261 |
| XareltoRivaroxaban | 13 | $17,590 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 21 | $13,102 |
| TradjentaLinagliptin | 18 | $12,021 |
| SymbicortBudesonide/Formoterol Fumarate | 26 | $7,025 |
| Varenicline Tartrate | 17 | $6,726 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 128 | $4,560 |
| Levothyroxine Sodium | 296 | $4,137 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Wegovy | $394 | $253,491232 claims |
| Lilly USA, LLCMounjaro | $924 | $212,936196 claims |
| PfizerEliquis | $276 | $97,40473 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $89 | $90,00799 claims |
| Boehringer IngelheimJardiance, Tradjenta | $129 | $79,85776 claims |
| MerckJanuvia | $420 | $59,57054 claims |
| GSKTrelegy Ellipta | $31 | $18,26127 claims |
| Johnson & JohnsonXarelto | $18 | $17,59013 claims |
| AbbVieSynthroid | $700 | $1,09923 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Hicksville
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
- Sally LauNew York$8.4M
- Angela BrancheRochester$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.